search
Back to results

Nasal Photodisinfection COVID-19 Proof of Concept Study

Primary Purpose

COVID-19, Corona Virus Infection, SARS-CoV 2

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Methylene-Blue Photodisinfection
Sponsored by
Sunnybrook Health Sciences Centre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for COVID-19 focused on measuring COVID-19, SARS-CoV-2, coronavirus, influenza, photodisinfection, nasal photodisinfection

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria (patient population):

  • Recent SARS-CoV-2+ diagnosis
  • Present in hospital

Inclusion Criteria (healthcare workers):

  • Recent SARS-CoV-2+ diagnosis
  • Ability to self-administer nasal swabs

Exclusion Criteria (patient population):

  • Immediate requirement for intubation (i.e. emergency airway) or inability to maintain independent oral airway

Exclusion Criteria (healthcare workers):

  • None

Sites / Locations

  • Sunnybrook Health Sciences Centre

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Methylene Blue-Photodisinfection

Arm Description

The Health-Canada approved Steriwave system (Ondine Biomedical, BC) will be used to deliver the Methylene Blue-Photodisinfection (MB-PDF) to the anterior nares.

Outcomes

Primary Outcome Measures

RT-qPCR
The main endpoint is microbiological; RT-qPCR will be conducted on the pre and post treatment swabs and the change in cycle threshold value will be measured

Secondary Outcome Measures

Full Information

First Posted
November 2, 2020
Last Updated
October 29, 2021
Sponsor
Sunnybrook Health Sciences Centre
search

1. Study Identification

Unique Protocol Identification Number
NCT04615936
Brief Title
Nasal Photodisinfection COVID-19 Proof of Concept Study
Official Title
Methylene Blue-mediated Photodisinfection for SARS-CoV-2 in the Upper Respiratory Tract
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
October 13, 2020 (Actual)
Primary Completion Date
July 7, 2021 (Actual)
Study Completion Date
October 19, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sunnybrook Health Sciences Centre

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study proposes to test photodisinfection (PDF) on SARS-CoV-2 in the nose. The study will use Health Canada approved Steriwave™ Nasal Decolonization (ND) in he nostril of patients infected with SARS-CoV-2. Participants are swabbed for SARS-CoV-2 before and after the PDF treatment. For the study, a small group of healthcare workers who have tested positive for SARS-CoV-2 will be included. They will not undergo the treatment but will need to swab their noses multiple times over the next 5 days. This nil group will provide the effect (if any) of swabbing SARS-CoV-2 levels in the nose.
Detailed Description
The study proposes to test photodisinfetion (PDF) on levels of SARS-CoV-2 in the nose. The study will use Health Canada approved Steriwave™ Nasal Decolonization (ND) in patients infected with SARS-CoV-2 . Currrently, PDF is being used at some institutions before surgery to lower the risk of postoperative infection. PDF uses a Methylene Blue (MB) nasal spray, followed by 5 minutes of red-light exposure through a small light-diffusing applicator. This will need to be placed into each nostril. Participants are swabbed for SARS-CoV-2 before and after treatment. In addition to the patients testing positive for SARS-CoV-2, there will also be a small group of healthcare workers who have tested positive that will be included. Though they are not undergoing treatment, they will swab their own noses multiple times over a period of 5 days. This will allow us to evaluate the effect (if any) of swabbing on SARS-CoV-2 levels in the nose. The study hypothesis is that MB-mediated PDF will show the ability to kill SARS-CoV-2 which will consequently confirm its efficacy as a first line defense against the virus.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19, Corona Virus Infection, SARS-CoV 2
Keywords
COVID-19, SARS-CoV-2, coronavirus, influenza, photodisinfection, nasal photodisinfection

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
There is only a single group of patients in the study who will undergo treatment. There is a small sub group/'nil' group of 3 healthcare workers that will not be undergoing the treatment but will instead be doing multiple nasal swabbing in the course of 5 days.
Masking
None (Open Label)
Masking Description
N/A- masking not required
Allocation
N/A
Enrollment
45 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Methylene Blue-Photodisinfection
Arm Type
Experimental
Arm Description
The Health-Canada approved Steriwave system (Ondine Biomedical, BC) will be used to deliver the Methylene Blue-Photodisinfection (MB-PDF) to the anterior nares.
Intervention Type
Other
Intervention Name(s)
Methylene-Blue Photodisinfection
Intervention Description
Participants will receive a pre-treatment nasal swab followed MB-PDF, this involves an MB nasal spray, followed by five minutes of red-light exposure into each nostril. Ten minutes after the treatment, a post treatment nasal swab will be performed.
Primary Outcome Measure Information:
Title
RT-qPCR
Description
The main endpoint is microbiological; RT-qPCR will be conducted on the pre and post treatment swabs and the change in cycle threshold value will be measured
Time Frame
30 minutes

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria (patient population): Recent SARS-CoV-2+ diagnosis Present in hospital Inclusion Criteria (healthcare workers): Recent SARS-CoV-2+ diagnosis Ability to self-administer nasal swabs Exclusion Criteria (patient population): Immediate requirement for intubation (i.e. emergency airway) or inability to maintain independent oral airway Exclusion Criteria (healthcare workers): None
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cari Whyne, PhD
Organizational Affiliation
Sunnybrook Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sunnybrook Health Sciences Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
35304729
Citation
Lobo CS, Rodrigues-Santos P, Pereira D, Nunez J, Trepa JCD, Sousa DL, Lourenco JV, Coelho MF, de Almeida LP, da Cunha JS, Arnaut LG. Photodynamic disinfection of SARS-CoV-2 clinical samples using a methylene blue formulation. Photochem Photobiol Sci. 2022 Jun;21(6):1101-1109. doi: 10.1007/s43630-022-00202-6. Epub 2022 Mar 19.
Results Reference
derived

Learn more about this trial

Nasal Photodisinfection COVID-19 Proof of Concept Study

We'll reach out to this number within 24 hrs